ClinicalTrials.gg
CompletedNCT02684006Updated Jul 30, 2025Results posted

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

A Phase 3 interventional study of Avelumab (MSB0010718C) and Axitinib (AG-013736) in Renal Cell Cancer, sponsored by Pfizer. Completed at 270 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
886
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing avelumab in Carcinoma, Renal Cell — 1 open to participants now, 2 under way, 1 of them phase 3. avelumab · Carcinoma, Renal Cell.

Enrollment
2nd of 10
886 · median 48
Started
2016
the only one that year
Phase 3
2 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
2 of 10
Pfizer

Among the 10 studies testing avelumab in Carcinoma, Renal Cell, this one is the 2nd largest by enrollment, is the only one that started in 2016, is one of 2 in phase 3, and was the 3rd registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

1 of the 10 studies testing avelumab in Carcinoma, Renal Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About avelumab

avelumab: first FDA approval 2017 (BAVENCIO), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing avelumab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma

03

Conditions studied

  • Renal Cell Cancer

Keywords

  • Cancer
  • renal cell cancer
  • kidney disease
  • kidney neoplasms
  • axitinib, sunitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed advanced or RCC with clear cell component
  • Availability of a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block from a de novo tumor during screening (biopsied tumor lesion should not be a target lesion). Alternatively, a recently obtained archival FFPE tumor tissue block (not cut slides) from a primary or metastatic tumor resection or biopsy can be provided if the following criteria are met: 1) the biopsy or resection was performed within 1 year of randomization AND 2) the patient has not received any intervening systemic anti-cancer treatment from the time the tissue was obtained and randomization onto the current study. If an FFPE tissue block cannot be provided as per documented regulations then, 15 unstained slides (10 minimum) will be acceptable
  • Availability of an archival FFPE tumor tissue from primary tumor resection specimen (if not provided per above). If an FFPE tissue block cannot be provided as per documented regulations 15 unstained slides (10 minimum) will be acceptable
  • At least one as defined by RECIST version 1.1 that has not been previously irradiated
  • (ECOG) performance status 0 or 1
  • Adequate bone marrow function, renal and liver functions

Exclusion criteria

Exclusion Criteria:

  • Prior systemic therapy directed at advanced or RCC
  • Prior or neoadjuvant therapy for RCC if disease progression or relapse has occurred during or within 12 months after the last dose of treatment.
  • Prior immunotherapy with IL-2, IFN-α, or anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti cytotoxic T lymphocyte associated antigen 4 (CTLA 4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways
  • Prior therapy with axitinib and/or sunitinib as well as any prior therapies with other VEGF pathway inhibitors
  • Newly diagnosed or active
  • Known severe reactions to monoclonal antibodies (Grade ≥3), any history of anaphylaxis, or uncontrolled asthma (ie, 3 or more features of partially controlled asthma Global Initiative for Asthma 2011)
  • Any of the following in the previous 12 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, less than LLN, pericardial effusion, cerebrovascular accident,
  • Any of the following in the previous 6 months: deep vein thrombosis or symptomatic pulmonary embolism
  • Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines (for example, inactivated influenza vaccines)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
886 participants (actual)

Study arms

  • Experimental
    Avelumab in combination with axitinib

    Avelumab administered at 10 mg/kg IV every two weeks in combination with axitinib, 5 mg PO BID.

    Drug: Avelumab (MSB0010718C) · Drug: Axitinib (AG-013736)

  • Active comparator
    Sunitinib

    Sunitinib given at 50 mg PO QD on schedule 4/2

    Drug: Sunitinib

Interventions

  • IV treatment Avelumab administered at 10 mg/kg IV every two weeks

  • Oral treatment Axitinib given 5 mg PO BID

    Also known as: Inlyta

  • Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2

    Also known as: Sutent

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants

    PFS: time from the date of randomization to the date of the first documentation of progressive disease (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST version \[v\] 1.1) or death due to any cause, whichever occurred first as assessed by BICR. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20 percent (%), increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute more than (\>) of at least 5 millimeter (mm). The appearance of one or more new lesions was also considered progression.

    Time frame: From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)

  2. Overall Survival (OS) in PD-L1 Positive Participants

    OS was defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.

    Time frame: From the date of randomization to the date of death due to any cause or censoring date, whichever occurred first (maximum up to approximately 89 months)

Secondary outcomes

  1. PFS as Assessed by BICR in Participants Irrespective of PD-L1 Expression

    PFS: time from the date of randomization to the date of the first documentation of PD or death due to any cause, whichever occurred first as assessed by BICR. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Time frame: From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)

  2. OS in Participants Irrespective of PD-L1 Expression

    OS was defined as the time (in months) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.

    Time frame: From the date of randomization to the date of death due to any cause or censoring date, whichever occurred first (maximum up to approximately 89 months)

  3. Percentage of Participants With Objective Response (OR) as Assessed by BICR Irrespective of PD-L1 Expression

    OR was defined as best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by BICR recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. 95% CI was based on Clopper-Pearson method.

    Time frame: From date of randomization until PD (maximum up to approximately 26 months)

  4. Percentage of Participants With OR as Assessed by Investigator Irrespective of PD-L1 Expression

    OR was defined as best overall response of CR or PR according to RECIST v1.1 as assessed by investigator recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. 95% CI was based on Clopper-Pearson method.

    Time frame: From date of randomization until PD (maximum up to approximately 89 months)

  5. Percentage of Participants With Disease Control (DC) as Assessed by BICR Irrespective of PD-L1 Expression

    DC was defined as a best overall response of CR, PR, non-CR/non-PD or stable disease (SD) according to RECIST v1.1 as assessed by BICR. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. All lymph nodes must decrease to normal size (short axis\<10mm). PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions. Non-CR/Non-PD was defined as persistence of any non-target lesions and/or tumor marker level above the normal limits. SD was defined as not to qualify for CR, PR or PD for target lesions and followed PR only if the sum increased by less than 20% from the nadir (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.

    Time frame: From date of randomization until PD (maximum up to approximately 26 months)

  6. Percentage of Participants With DC as Assessed by Investigator Irrespective of PD-L1 Expression

    DC was defined as a best overall response of CR, PR, non-CR/non-PD or SD according to RECIST v1.1 as assessed by investigator. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. All lymph nodes must decrease to normal size (short axis\<10mm). PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions. Non-CR/Non-PD was defined as persistence of any non-target lesions and/or tumor marker level above the normal limits. SD was defined as not to qualify for CR, PR or PD for target lesions and followed PR only if the sum increased by less than 20% from the nadir (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.

    Time frame: From date of randomization until PD (maximum up to approximately 89 months)

  7. Time to Tumor Response (TTR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression

    TTR was defined as the time from randomization to the first documentation of objective tumor response according to RECIST v1.1 as assessed by BICR (CR or PR) which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

    Time frame: From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 26 months)

  8. TTR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression

    TTR was defined as the time from randomization to the first documentation of objective tumor response according to RECIST v1.1 as assessed by investigator (CR or PR) which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

    Time frame: From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 89 months)

  9. Duration of Response (DR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression

    BICR assessed DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of objective tumor progression assessed by BICR or death due to any cause whichever occurred first. As per RECIST v1.1. CR: complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD: at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Time frame: From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 26 months)

  10. DR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression

    Investigator assessed DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of objective tumor progression (PD) assessed by investigator or death due to any cause whichever occurred first. As per RECIST v1.1. CR: complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD: at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Time frame: From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 89 months)

  11. PFS as Assessed by Investigator in Participants Irrespective of PD-L1 Expression

    Investigator assessed PFS: time from the date of randomization to the date of the first documentation of PD according to RECIST v1.1 or death due to any cause, whichever occurred first. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Time frame: From date of randomization until PD, whichever occurred first (maximum up to approximately 89 months)

  12. Progression-Free Survival on Next-line Therapy (PFS2) in Participants Irrespective of PD-L1 Expression

    PFS2 is defined as the time (in months) from randomization to discontinuation of next-line treatment after first objective disease progression by investigator assessment, second objective disease progression by investigator assessment after initiation of next-line treatment, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Time frame: From date of randomization until PD or death, whichever occurred first (maximum up to approximately 89 months)

  13. Number of Participants With Treatment-Emergent Adverse Events (AEs) Graded Based on National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (V) 4.03

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event was during the on-treatment period (time from the first dose of study treatment through 90 days after last dose of study treatment or start day of new anti-cancer drug therapy-1 day). As per NCI-CTCAE v4.03, grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death.

    Time frame: From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months)

  14. Number of Participants According to Grade Shift in Hematology Parameters

    Following hematology parameters were assessed: hemoglobin decreased (anemia), hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and white blood cell (WBC) decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 4.03 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe, G4=life-threatening consequences and G5=death. Baseline was defined as last assessment prior to first dose of study treatment. Number of participants with a baseline grade of 0 to 4 which shifted to G3-4 post-baseline are reported in this outcome measure. Only non-zero categories for any reporting arm are reported.

    Time frame: From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months)

  15. Number of Participants According to Grade Shift in Chemistry Parameters

    Following chemistry parameters were assessed: alanine aminotransferase(ALT) increased, alkaline phosphatase(ALP) increased, aspartate aminotransferase(AST) increased, blood bilirubin increased, cholesterol high, creatinine phosphokinase(CPK) increased, creatinine increased, gamma glutamyl transferase(GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesmia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased and serum amylase increased. Laboratory abnormality graded as per NCI CTCAE v4.03; G0=non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe, G4=life-threatening consequences and G5=death. Number of participants with a baseline grade of 0 to 4 which shifted to G3-4 post-baseline are reported. Only non-zero categories for any reporting arm are reported.

    Time frame: From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months)

  16. Change From Baseline in Vital Signs - Blood Pressure at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and End of Treatment (EOT) Visit

    Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured with the participant in the seated position after the participant had been sitting quietly for at least 5 minutes.

    Time frame: Baseline (pre-dose on Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 4, 5, 6, 7, EOT visit (maximum up to approximately 89 months) (each cycle=42 days)

  17. Change From Baseline in Vital Signs - Pulse Rate at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and EOT Visit

    Pulse rate was measured with the participant in the seated position after the participant had been sitting quietly for at least 5 minutes.

    Time frame: Baseline (pre-dose on Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 4, 5, 6, 7, EOT visit (maximum up to approximately 89 months) (each cycle=42 days)

  18. Number of Participants Who Discontinued Treatment Due to Toxicity

    Number of participants who discontinued treatment due to toxicity are reported in this outcome measure.

    Time frame: From first dose of study treatment until discontinuation of study treatment (maximum up to approximately 89 months)

  19. Time to Treatment Discontinuation/Failure Due to Toxicity

    Time to treatment discontinuation/ failure due to toxicity was defined as the time from first dose of study treatment to discontinuation of study treatment due to an adverse event or death due to study treatment toxicity.

    Time frame: From first dose of study treatment until discontinuation of study treatment (maximum up to approximately 89 months)

  20. Trough Plasma Concentration (Ctrough) of Avelumab

    Predose concentration during multiple dosing.

    Time frame: Pre dose (0 hour) on Day 1, 15 and 29 of Cycle 1, Day 1 and 29 of Cycles 2, 3, 4 and Day 1 of Cycle 6

  21. Ctrough of Axitinib

    Predose concentration during multiple dosing.

    Time frame: Pre dose (0 hour) on day 15 and 29 of cycle 1 (each cycle= 6 weeks)

  22. Maximum Plasma Concentration (Cmax) of Axitinib

    Time frame: 2 hours post-dose on Day 1, pre-dose and 2 hours post dose on Days 15 and 29 of Cycle 1

  23. Number of Participants With Positive PD-L1 Biomarker Expression in Pre-treatment Tumor Tissue

    Tumor biospecimens from pre-treatment tissue samples were analyzed by immunohistochemistry for PD-L1 biomarker expression. Number of participants with positive PD-L1 biomarker expression are reported in this outcome measure.

    Time frame: At screening

  24. PFS in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups

    PFS: time from the date of randomization to the date of the first documentation of PD according to RECIST v1.1 or death due to any cause, whichever occurred first. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Time frame: From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)

  25. Percentage of Participants With OR in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups

    OR was defined as best overall response of CR or PR according to RECIST v1.1 as assessed by BICR recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

    Time frame: From date of randomization until PD (maximum up to approximately 26 months)

  26. Percentage of Participants With DC in Biomarker-Positive Subgroup

    DC was defined as a best overall response of CR, PR, or stable disease (SD) according to the RECIST v.1.1 recorded from randomization until disease progression or death due to any cause, whichever occurred first. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. SD was defined as PR that the sum increases by less than 20% from the nadir, (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.

    Time frame: From date of randomization until PD or death, whichever occurred first (maximum up to approximately 26 months)

  27. TTR in Biomarker-Positive Subgroup

    TTR was defined as the time from randomization to the first documentation of objective tumor response (CR or PR) according to RECIST v1.1 which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

    Time frame: From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 26 months)

  28. DR in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups

    DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of PD or death due to any cause, whichever occurred first. As per RECIST version 1.1, CR: disappearance of all target and non-target lesions, and sustained for at least 4 weeks. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10 mm. PR: at least 30%\< in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions. PD: defined as at least a 20% \> in sum of diameters of target lesions, taking as reference the smallest sum on study (this included baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute increase of at least 5 mm. Appearance of one or more new lesions was also considered progression.

    Time frame: From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 26 months)

  29. Number of Participants With Positive Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb) of Avelumab When Used in Combination With Axitinib

    Time frame: From start of treatment until 30 days after the end of avelumab treatment (maximum up to approximately 89 months)

  30. Time to Symptom Deterioration (TTD) for Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index - Disease Related Symptoms (FKSI-DRS)

    TTD was defined as the time from date of randomization to the first time the participant's score showed a 3-point or greater decrease in FKSI-DRS. FKSI was used to assess symptoms and quality of life (QoL) for those diagnosed with advanced kidney cancer and it consisted of 19 questions. A 9-item subscale of the FKSI known as FKSI-Disease Related Symptoms subscale (FKSI-DRS). This subscale included 9 items: lack of energy, pain, losing weight, bone pain, fatigue, shortness of breath, coughing, bothered by fevers, and hematuria. Each of the 9 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI-DRS score = sum of the 9 item scores; total range: 0 - 36; 0 (no symptoms) to 36 (very much); higher score indicated greater presence of symptoms.

    Time frame: Date of randomization to the first time the participant's score showed a 3-point or greater decrease in FKSI-DRS (maximum up to approximately 26 months)

  31. Change From Baseline in European Quality of Life (EuroQol) 5-Dimension 5 Levels (EQ-5D-5L) Utility Score

    EQ-5D-5L is a 5-item participant-completed questionnaire designed to assess health status in terms of a single utility score. EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Overall scores ranged from 0 to 1, with low scores representing a higher level of dysfunction. Published UK weights were used to create a single summary utility score. Utility scores range from -0.594 to 1, with higher scores representing better health status.

    Time frame: Baseline, Day 1 of Cycle 2 to Cycle 60, End of treatment (any Day from Day 1 of dosing; maximum up to approximately 89 months)

  32. Change From Baseline in EQ-5D Visual Analogue Scale (VAS) Score

    EQ-VAS records the participant's self-rated health status from 0 (worst imaginable health status) to 100 (best imaginable health status), where higher scores indicated better health status.

    Time frame: Baseline, Day 1 of Cycle 2 to Cycle 60, End of treatment (any Day from Day 1 of dosing; maximum up to approximately 89 months)

07

Results

Posted Oct 29, 2024

Participant flow

Participant flow — Overall Study
MilestoneAvelumab + AxitinibSunitinib
Started442444
Completed00
Not completed442444
Withdrew: Other186
Withdrew: Protocol violation21
Withdrew: Non-compliance with study drug11
Withdrew: No longer met eligibility criteria62
Withdrew: Lost to follow-up01
Withdrew: Death2522
Withdrew: Global deterioration of health status1820
Withdrew: Physician decision158
Withdrew: Adverse event8665
Withdrew: Withdrawal by subject2943
Withdrew: Progressive disease236266
Withdrew: Participation terminated by sponsor69

Outcome measures

PrimaryProgression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants

PFS: time from the date of randomization to the date of the first documentation of progressive disease (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST version \[v\] 1.1) or death due to any cause, whichever occurred first as assessed by BICR. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20 percent (%), increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute more than (\>) of at least 5 millimeter (mm). The appearance of one or more new lesions was also considered progression.

Time frame:
From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)
Reported as:
Median · Months
Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants
MonthsAvelumab + AxitinibSunitinib
Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants13.8 (11.1 to NA)7.2 (5.7 to 9.7)
Statistical analysis
  • Avelumab + Axitinib vs Sunitinib · Log Rank · p = 0.0001 (2-sided p-value) · Hazard ratio (hr): 0.61 · 95% CI 0.475 to 0.790
PrimaryOverall Survival (OS) in PD-L1 Positive Participants

OS was defined as the time from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.

Time frame:
From the date of randomization to the date of death due to any cause or censoring date, whichever occurred first (maximum up to approximately 89 months)
Reported as:
Median · Months
Overall Survival (OS) in PD-L1 Positive Participants
MonthsAvelumab + AxitinibSunitinib
Overall Survival (OS) in PD-L1 Positive Participants43.2 (36.5 to 51.7)36.2 (29.8 to 44.2)
Statistical analysis
  • Avelumab + Axitinib vs Sunitinib · Log Rank · p = 0.1509 (2-sided p-value) · Hazard ratio (hr): 0.86 · 95% CI 0.701 to 1.057
SecondaryPFS as Assessed by BICR in Participants Irrespective of PD-L1 Expression

PFS: time from the date of randomization to the date of the first documentation of PD or death due to any cause, whichever occurred first as assessed by BICR. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.

Time frame:
From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)
Reported as:
Median · Months
PFS as Assessed by BICR in Participants Irrespective of PD-L1 Expression
MonthsAvelumab + AxitinibSunitinib
PFS as Assessed by BICR in Participants Irrespective of PD-L1 Expression13.8 (11.1 to NA)8.4 (6.9 to 11.1)
Statistical analysis
  • Avelumab + Axitinib vs Sunitinib · Log Rank · p = 0.0002 (2-sided p-value) · Hazard ratio (hr): 0.69 · 95% CI 0.563 to 0.840
SecondaryOS in Participants Irrespective of PD-L1 Expression

OS was defined as the time (in months) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.

Time frame:
From the date of randomization to the date of death due to any cause or censoring date, whichever occurred first (maximum up to approximately 89 months)
Reported as:
Median · Months
OS in Participants Irrespective of PD-L1 Expression
MonthsAvelumab + AxitinibSunitinib
OS in Participants Irrespective of PD-L1 Expression44.8 (39.7 to 51.1)38.9 (31.4 to 45.2)
Statistical analysis
  • Avelumab + Axitinib vs Sunitinib · Log Rank · p = 0.1338 (2-sided p-value) · Hazard ratio (hr): 0.88 · 95% CI 0.749 to 1.039
SecondaryPercentage of Participants With Objective Response (OR) as Assessed by BICR Irrespective of PD-L1 Expression

OR was defined as best overall response of complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by BICR recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. 95% CI was based on Clopper-Pearson method.

Time frame:
From date of randomization until PD (maximum up to approximately 26 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR) as Assessed by BICR Irrespective of PD-L1 Expression
Percentage of participantsAvelumab + AxitinibSunitinib
Percentage of Participants With Objective Response (OR) as Assessed by BICR Irrespective of PD-L1 Expression51.4 (46.6 to 56.1)25.7 (21.7 to 30.0)
SecondaryPercentage of Participants With OR as Assessed by Investigator Irrespective of PD-L1 Expression

OR was defined as best overall response of CR or PR according to RECIST v1.1 as assessed by investigator recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. 95% CI was based on Clopper-Pearson method.

Time frame:
From date of randomization until PD (maximum up to approximately 89 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With OR as Assessed by Investigator Irrespective of PD-L1 Expression
Percentage of participantsAvelumab + AxitinibSunitinib
Percentage of Participants With OR as Assessed by Investigator Irrespective of PD-L1 Expression59.7 (55.0 to 64.3)32.0 (27.7 to 36.5)
SecondaryPercentage of Participants With Disease Control (DC) as Assessed by BICR Irrespective of PD-L1 Expression

DC was defined as a best overall response of CR, PR, non-CR/non-PD or stable disease (SD) according to RECIST v1.1 as assessed by BICR. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. All lymph nodes must decrease to normal size (short axis\<10mm). PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions. Non-CR/Non-PD was defined as persistence of any non-target lesions and/or tumor marker level above the normal limits. SD was defined as not to qualify for CR, PR or PD for target lesions and followed PR only if the sum increased by less than 20% from the nadir (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.

Time frame:
From date of randomization until PD (maximum up to approximately 26 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Control (DC) as Assessed by BICR Irrespective of PD-L1 Expression
Percentage of participantsAvelumab + AxitinibSunitinib
Percentage of Participants With Disease Control (DC) as Assessed by BICR Irrespective of PD-L1 Expression82.8 (79.0 to 86.2)73.4 (69.1 to 77.5)
SecondaryPercentage of Participants With DC as Assessed by Investigator Irrespective of PD-L1 Expression

DC was defined as a best overall response of CR, PR, non-CR/non-PD or SD according to RECIST v1.1 as assessed by investigator. CR was defined as complete disappearance of all target and non-target lesions, with the exception of nodal disease and sustained for at least 4 weeks. All lymph nodes must decrease to normal size (short axis\<10mm). PR was defined as at least 30% decrease in the sum of the longest dimensions of target lesions taking as reference the baseline sum longest dimensions. Non-CR/Non-PD was defined as persistence of any non-target lesions and/or tumor marker level above the normal limits. SD was defined as not to qualify for CR, PR or PD for target lesions and followed PR only if the sum increased by less than 20% from the nadir (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.

Time frame:
From date of randomization until PD (maximum up to approximately 89 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With DC as Assessed by Investigator Irrespective of PD-L1 Expression
Percentage of participantsAvelumab + AxitinibSunitinib
Percentage of Participants With DC as Assessed by Investigator Irrespective of PD-L1 Expression85.1 (81.4 to 88.3)76.4 (72.1 to 80.2)
SecondaryTime to Tumor Response (TTR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression

TTR was defined as the time from randomization to the first documentation of objective tumor response according to RECIST v1.1 as assessed by BICR (CR or PR) which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

Time frame:
From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 26 months)
Reported as:
Median · Months
Time to Tumor Response (TTR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression
MonthsAvelumab + AxitinibSunitinib
Time to Tumor Response (TTR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression2.6 (1.2 to 13.8)3.2 (1.2 to 11.6)
SecondaryTTR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression

TTR was defined as the time from randomization to the first documentation of objective tumor response according to RECIST v1.1 as assessed by investigator (CR or PR) which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

Time frame:
From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 89 months)
Reported as:
Median · Months
TTR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression
MonthsAvelumab + AxitinibSunitinib
TTR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression2.8 (1.1 to 34.5)2.8 (1.2 to 65.2)
SecondaryDuration of Response (DR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression

BICR assessed DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of objective tumor progression assessed by BICR or death due to any cause whichever occurred first. As per RECIST v1.1. CR: complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD: at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.

Time frame:
From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 26 months)
Reported as:
Median · Months
Duration of Response (DR) as Assessed by BICR in Participants Irrespective of PD-L1 Expression
MonthsAvelumab + AxitinibSunitinib
Duration of Response (DR) as Assessed by BICR in Participants Irrespective of PD-L1 ExpressionNA (NA to NA)NA (11.2 to NA)
SecondaryDR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression

Investigator assessed DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of objective tumor progression (PD) assessed by investigator or death due to any cause whichever occurred first. As per RECIST v1.1. CR: complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD: at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.

Time frame:
From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 89 months)
Reported as:
Median · Months
DR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression
MonthsAvelumab + AxitinibSunitinib
DR as Assessed by Investigator in Participants Irrespective of PD-L1 Expression19.4 (16.4 to 22.3)14.5 (8.7 to 16.6)
SecondaryPFS as Assessed by Investigator in Participants Irrespective of PD-L1 Expression

Investigator assessed PFS: time from the date of randomization to the date of the first documentation of PD according to RECIST v1.1 or death due to any cause, whichever occurred first. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.

Time frame:
From date of randomization until PD, whichever occurred first (maximum up to approximately 89 months)
Reported as:
Median · Months
PFS as Assessed by Investigator in Participants Irrespective of PD-L1 Expression
MonthsAvelumab + AxitinibSunitinib
PFS as Assessed by Investigator in Participants Irrespective of PD-L1 Expression13.9 (11.1 to 16.6)8.5 (8.2 to 9.7)
Statistical analysis
  • Avelumab + Axitinib vs Sunitinib · Log Rank · p = <.0001 (2-sided p-value) · Hazard ratio (hr): 0.66 · 95% CI 0.565 to 0.768
SecondaryProgression-Free Survival on Next-line Therapy (PFS2) in Participants Irrespective of PD-L1 Expression

PFS2 is defined as the time (in months) from randomization to discontinuation of next-line treatment after first objective disease progression by investigator assessment, second objective disease progression by investigator assessment after initiation of next-line treatment, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.

Time frame:
From date of randomization until PD or death, whichever occurred first (maximum up to approximately 89 months)
Reported as:
Median · Months
Progression-Free Survival on Next-line Therapy (PFS2) in Participants Irrespective of PD-L1 Expression
MonthsAvelumab + AxitinibSunitinib
Progression-Free Survival on Next-line Therapy (PFS2) in Participants Irrespective of PD-L1 Expression30.4 (25.8 to 34.6)19.4 (17.0 to 22.4)
Statistical analysis
  • Avelumab + Axitinib vs Sunitinib · Hazard ratio (hr): 0.64 · 95% CI 0.551 to 0.754
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) Graded Based on National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (V) 4.03

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were those events with onset dates occurring during the on-treatment period for the first time, or if the worsening of an event was during the on-treatment period (time from the first dose of study treatment through 90 days after last dose of study treatment or start day of new anti-cancer drug therapy-1 day). As per NCI-CTCAE v4.03, grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death.

Time frame:
From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) Graded Based on National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (V) 4.03
ParticipantsAvelumab + AxitinibSunitinib
Grade 1517
Grade 26473
Grade 3271268
Grade 46454
Grade 53024
SecondaryNumber of Participants According to Grade Shift in Hematology Parameters

Following hematology parameters were assessed: hemoglobin decreased (anemia), hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and white blood cell (WBC) decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 4.03 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe, G4=life-threatening consequences and G5=death. Baseline was defined as last assessment prior to first dose of study treatment. Number of participants with a baseline grade of 0 to 4 which shifted to G3-4 post-baseline are reported in this outcome measure. Only non-zero categories for any reporting arm are reported.

Time frame:
From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months)
Reported as:
Count of participants · Participants
Number of Participants According to Grade Shift in Hematology Parameters
ParticipantsAvelumab + AxitinibSunitinib
Anemia (Baseline G0 to post-baseline G3-4)39
Anemia (Baseline G1 to post-baseline G3-4)621
Anemia (Baseline G2 to post-baseline G3-4)414
Anemia (Baseline G3 to post-baseline G3-4)02
Lymphocytes count decreased (Baseline G0 to post-baseline G3-4)2153
Lymphocytes count decreased (Baseline G1 to post-baseline G3-4)1118
Lymphocytes count decreased (Baseline G2 to post-baseline G3-4)715
Lymphocytes count decreased (Baseline G3 to post-baseline G3-4)26
Neutrophils count decreased (Baseline G0 to post-baseline G3-4)7108
Neutrophils count decreased (Baseline G1 to post-baseline G3-4)02
Neutrophils count decreased (Baseline G2 to post-baseline G3-4)01
Platelets count decreased (Baseline G0 to post-baseline G3-4)361
Platelets count decreased (Baseline G1 to post-baseline G3-4)16
WBC decreased (Baseline G0 to post-baseline G3-4)135
WBC decreased (Baseline G1 to post-baseline G3-4)07
WBC decreased (Baseline G2 to post-baseline G3-4)02
SecondaryNumber of Participants According to Grade Shift in Chemistry Parameters

Following chemistry parameters were assessed: alanine aminotransferase(ALT) increased, alkaline phosphatase(ALP) increased, aspartate aminotransferase(AST) increased, blood bilirubin increased, cholesterol high, creatinine phosphokinase(CPK) increased, creatinine increased, gamma glutamyl transferase(GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesmia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased and serum amylase increased. Laboratory abnormality graded as per NCI CTCAE v4.03; G0=non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe, G4=life-threatening consequences and G5=death. Number of participants with a baseline grade of 0 to 4 which shifted to G3-4 post-baseline are reported. Only non-zero categories for any reporting arm are reported.

Time frame:
From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months)
Reported as:
Count of participants · Participants
Number of Participants According to Grade Shift in Chemistry Parameters
ParticipantsAvelumab + AxitinibSunitinib
ALT increased (Baseline G0 to post-baseline G3-4)4219
ALT increased (Baseline G1 to post-baseline G3-4)30
ALP increased (Baseline G0 to post-baseline G3-4)90
ALP increased (Baseline G1 to post-baseline G3-4)56
ALP increased (Baseline G2 to post-baseline G3-4)13
ALP increased (Baseline G3 to post-baseline G3-4)41
AST increased (Baseline G0 to post-baseline G3-4)2616
AST increased (Baseline G1 to post-baseline G3-4)64
AST increased (Baseline G3 to post-baseline G3-4)10
Blood bilirubin increased (Baseline G0 to post-baseline G3-4)36
Blood bilirubin increased (Baseline G1 to post-baseline G3-4)20
Cholesterol high (Baseline G0 to post-baseline G3-4)83
Cholesterol high (Baseline G1 to post-baseline G3-4)43
Cholesterol high (Baseline G2 to post-baseline G3-4)01
CPK increased (Baseline G0 to post-baseline G3-4)77
CPK increased (Baseline G2 to post-baseline G3-4)01
CPK increased (Baseline G1 to post-baseline G3-4)02
CPK increased (Baseline G3 to post-baseline G3-4)10
Creatinine increased (Baseline G0 to post-baseline G3-4)72
Creatinine increased (Baseline G1 to post-baseline G3-4)45
Creatinine increased (Baseline G2 to post-baseline G3-4)01
Creatinine increased (Baseline G3 to post-baseline G3-4)01
GGT increased (Baseline G0 to post-baseline G3-4)1516
GGT increased (Baseline G1 to post-baseline G3-4)207
GGT increased (Baseline G2 to post-baseline G3-4)124
GGT increased (Baseline G3 to post-baseline G3-4)72
GGT increased (Baseline G4 to post-baseline G3-4)01
Hypercalcemia (Baseline G0 to post-baseline G3-4)44
Hypercalcemia (Baseline G1 to post-baseline G3-4)12
Hypercalcemia (Baseline G2 to post-baseline G3-4)11
Hypercalcemia (Baseline G3 to post-baseline G3-4)02
Hypercalcemia (Baseline G4 to post-baseline G3-4)01
Hyperglycemia (Baseline G0 to post-baseline G3-4)3720
Hyperglycemia (Baseline G1 to post-baseline G3-4)43
Hyperglycemia (Baseline G2 to post-baseline G3-4)53
Hyperglycemia (Baseline G3 to post-baseline G3-4)64
Hyperkalemia (Baseline G0 to post-baseline G3-4)1916
Hyperkalemia (Baseline G1 to post-baseline G3-4)15
Hyperkalemia (Baseline G2 to post-baseline G3-4)33
Hyperkalemia (Baseline G3 to post-baseline G3-4)10
Hyperkalemia (Baseline G4 to post-baseline G3-4)01
Hypermagnesemia (Baseline G0 to post-baseline G3-4)1320
Hypermagnesemia (Baseline G1 to post-baseline G3-4)12
Hypernatremia (Baseline G0 to post-baseline G3-4)72
Hypertriglyceridemia (Baseline G0 to post-baseline G3-4)183
Hypertriglyceridemia (Baseline G1 to post-baseline G3-4)3123
Hypertriglyceridemia (Baseline G2 to post-baseline G3-4)156
Hypertriglyceridemia (Baseline G3 to post-baseline G3-4)45
Hypertriglyceridemia (Baseline G4 to post-baseline G3-4)01
Hypoalbunemia (Baseline G0 to post-baseline G3-4)36
Hypoalbunemia (Baseline G1 to post-baseline G3-4)11
Hypoalbunemia (Baseline G2 to post-baseline G3-4)22
Hypoalbunemia (Baseline G3 to post-baseline G3-4)12
Hypocalcemia (Baseline G0 to post-baseline G3-4)44
Hypocalcemia (Baseline G1 to post-baseline G3-4)01
Hypocalcemia (Baseline G2 to post-baseline G3-4)10
Hypoglycemia (Baseline G0 to post-baseline G3-4)21
Hypokalemia (Baseline G0 to post-baseline G3-4)1715
Hypokalemia (Baseline G2 to post-baseline G3-4)21
Hypomagnesemia (Baseline G0 to post-baseline G3-4)31
Hypomagnesemia (Baseline G1 to post-baseline G3-4)21
Hypomagnesemia (Baseline G2 to post-baseline G3-4)10
Hyponatremia (Baseline G0 to post-baseline G3-4)4235
Hyponatremia (Baseline G1 to post-baseline G3-4)1914
Hyponatremia (Baseline G3 to post-baseline G3-4)12
Lipase increased (Baseline G0 to post-baseline G3-4)6327
Lipase increased (Baseline G1 to post-baseline G3-4)198
Lipase increased (Baseline G2 to post-baseline G3-4)73
Lipase increased (Baseline G3 to post-baseline G3-4)27
Lipase increased (Baseline G4 to post-baseline G3-4)10
Serum amylase increased (Baseline G0 to post-baseline G3-4)214
Serum amylase increased (Baseline G1 to post-baseline G3-4)124
Serum amylase increased (Baseline G2 to post-baseline G3-4)44
Serum amylase increased (Baseline G3 to post-baseline G3-4)13
SecondaryChange From Baseline in Vital Signs - Blood Pressure at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and End of Treatment (EOT) Visit

Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured with the participant in the seated position after the participant had been sitting quietly for at least 5 minutes.

Time frame:
Baseline (pre-dose on Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 4, 5, 6, 7, EOT visit (maximum up to approximately 89 months) (each cycle=42 days)
Reported as:
Mean · Millimeters of mercury
Change From Baseline in Vital Signs - Blood Pressure at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and End of Treatment (EOT) Visit
Millimeters of mercuryAvelumab + AxitinibSunitinib
Baseline: Sitting SBP126.5 ± 13.52126.3 ± 12.00
Change at Cycle 2, Day 1: Sitting SBP4.7 ± 16.080.8 ± 12.49
Change at Cycle 3, Day 1: Sitting SBP3.8 ± 16.431.2 ± 12.81
Change at Cycle 4, Day 1: Sitting SBP3.0 ± 15.950.1 ± 13.01
Change at Cycle 5, Day 1: Sitting SBP2.5 ± 15.42-0.1 ± 12.26
Change at Cycle 6, Day 1: Sitting SBP1.6 ± 15.39-0.1 ± 12.97
Change at Cycle 7, Day 1: Sitting SBP1.9 ± 15.390.4 ± 13.56
Change at End of Treatment: Sitting SBP0.9 ± 17.401.7 ± 15.67
Baseline: Sitting DBP75.7 ± 9.3275.9 ± 9.41
Change at Cycle 2, Day 1: Sitting DBP5.8 ± 10.92-0.1 ± 8.60
Change at Cycle 3, Day 1: Sitting DBP4.9 ± 10.980.0 ± 9.64
Change at Cycle 4, Day 1: Sitting DBP4.8 ± 11.61-1.9 ± 9.30
Change at Cycle 5, Day 1: Sitting DBP4.5 ± 11.17-1.9 ± 9.71
Change at Cycle 6, Day 1: Sitting DBP3.8 ± 10.18-1.3 ± 9.89
Change at Cycle 7, Day 1: Sitting DBP3.8 ± 11.04-1.1 ± 9.90
Change at End of Treatment: Sitting DBP1.5 ± 12.70-0.9 ± 10.92
SecondaryChange From Baseline in Vital Signs - Pulse Rate at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and EOT Visit

Pulse rate was measured with the participant in the seated position after the participant had been sitting quietly for at least 5 minutes.

Time frame:
Baseline (pre-dose on Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 4, 5, 6, 7, EOT visit (maximum up to approximately 89 months) (each cycle=42 days)
Reported as:
Mean · beats per minute
Change From Baseline in Vital Signs - Pulse Rate at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and EOT Visit
beats per minuteAvelumab + AxitinibSunitinib
Baseline75.4 ± 12.4975.6 ± 12.63
Change at Cycle 2, Day 10.4 ± 12.773.1 ± 10.69
Change at Cycle 3, Day 10.8 ± 12.583.1 ± 11.34
Change at Cycle 4, Day 1-0.6 ± 12.792.8 ± 10.34
Change at Cycle 5, Day 1-0.5 ± 12.002.5 ± 10.82
Change at Cycle 6, Day 1-1.9 ± 12.371.6 ± 10.75
Change at Cycle 7, Day 1-1.9 ± 11.692.1 ± 10.13
Change at End of Treatment2.9 ± 15.293.5 ± 12.27
SecondaryNumber of Participants Who Discontinued Treatment Due to Toxicity

Number of participants who discontinued treatment due to toxicity are reported in this outcome measure.

Time frame:
From first dose of study treatment until discontinuation of study treatment (maximum up to approximately 89 months)
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Treatment Due to Toxicity
ParticipantsAvelumab + AxitinibSunitinib
Number of Participants Who Discontinued Treatment Due to Toxicity136 (17.41 to —)65 (12.82 to —)
SecondaryTime to Treatment Discontinuation/Failure Due to Toxicity

Time to treatment discontinuation/ failure due to toxicity was defined as the time from first dose of study treatment to discontinuation of study treatment due to an adverse event or death due to study treatment toxicity.

Time frame:
From first dose of study treatment until discontinuation of study treatment (maximum up to approximately 89 months)
Reported as:
Mean · Months
Time to Treatment Discontinuation/Failure Due to Toxicity
MonthsAvelumab + AxitinibSunitinib
Time to Treatment Discontinuation/Failure Due to Toxicity13.5 ± 17.4110.5 ± 12.82
SecondaryTrough Plasma Concentration (Ctrough) of Avelumab

Predose concentration during multiple dosing.

Time frame:
Pre dose (0 hour) on Day 1, 15 and 29 of Cycle 1, Day 1 and 29 of Cycles 2, 3, 4 and Day 1 of Cycle 6
Reported as:
Geometric mean · Micrograms per milliliter
Trough Plasma Concentration (Ctrough) of Avelumab
Micrograms per milliliterAvelumab + Axitinib
Cycle 1 (day 1)4.218 ± 1232
Cycle 1 (day 15)18.69 ± 102
Cycle 1 (day 29)21.99 ± 96
Cycle 2 (day 1)24.87 ± 92
Cycle 2 (day 29)22.62 ± 113
Cycle 3 (day 1)26.04 ± 98
Cycle 3 (day 29)30.13 ± 82
Cycle 4 (day 1)29.15 ± 98
Cycle 4 (day 29)31.38 ± 86
Cycle 6 (day 1)39.11 ± 58
SecondaryCtrough of Axitinib

Predose concentration during multiple dosing.

Time frame:
Pre dose (0 hour) on day 15 and 29 of cycle 1 (each cycle= 6 weeks)
Reported as:
Geometric mean · Nanograms per milliliter
Ctrough of Axitinib
Nanograms per milliliterAvelumab + Axitinib
Cycle1 (day 15)4.904 ± 172
Cycle1 (day 29)6.272 ± 174
SecondaryMaximum Plasma Concentration (Cmax) of Axitinib
Time frame:
2 hours post-dose on Day 1, pre-dose and 2 hours post dose on Days 15 and 29 of Cycle 1
Reported as:
Geometric mean · Nanogram per milliliter
Maximum Plasma Concentration (Cmax) of Axitinib
Nanogram per milliliterAvelumab + Axitinib
Cycle1 (day 1); Post Dose17.93 ± 182
Cycle1 (day 15); Pre-Dose4.904 ± 172
Cycle1 (day 15); Post Dose18.45 ± 157
Cycle1 (day 29); Pre-Dose6.272 ± 174
Cycle1 (day 29); Post Dose17.19 ± 174
SecondaryNumber of Participants With Positive PD-L1 Biomarker Expression in Pre-treatment Tumor Tissue

Tumor biospecimens from pre-treatment tissue samples were analyzed by immunohistochemistry for PD-L1 biomarker expression. Number of participants with positive PD-L1 biomarker expression are reported in this outcome measure.

Time frame:
At screening
Reported as:
Count of participants · Participants
Number of Participants With Positive PD-L1 Biomarker Expression in Pre-treatment Tumor Tissue
ParticipantsAvelumab + AxitinibSunitinib
Number of Participants With Positive PD-L1 Biomarker Expression in Pre-treatment Tumor Tissue266288
SecondaryPFS in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups

PFS: time from the date of randomization to the date of the first documentation of PD according to RECIST v1.1 or death due to any cause, whichever occurred first. PFS data was censored on date of last adequate tumor assessment for participants who did not have an event (PD or death), who started new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing tumor assessments. PD was defined as at least a 20% increase in the sum of all the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to relative increase of 20 %, sum must have also demonstrated an absolute \> of at least 5 mm. The appearance of one or more new lesions was also considered progression.

Time frame:
From date of randomization to the first documentation of PD or death due to any cause or censoring date, whichever occurred first (maximum up to approximately 26 months)
Reported as:
Median · Months
PFS in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups
MonthsAvelumab + AxitinibSunitinib
PD-L1 Positive Tumors13.8 (11.1 to NA)7.2 (5.7 to 9.7)
PD-L1 Negative Tumors16.1 (9.7 to NA)11.1 (6.9 to 17.3)
SecondaryPercentage of Participants With OR in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups

OR was defined as best overall response of CR or PR according to RECIST v1.1 as assessed by BICR recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

Time frame:
From date of randomization until PD (maximum up to approximately 26 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With OR in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups
Percentage of participantsAvelumab + AxitinibSunitinib
PD-L1 Positive Tumors55.2 (49.0 to 61.2)25.5 (20.6 to 30.9)
PD-L1 Negative Tumors47.0 (38.2 to 55.8)28.3 (20.5 to 37.3)
SecondaryPercentage of Participants With DC in Biomarker-Positive Subgroup

DC was defined as a best overall response of CR, PR, or stable disease (SD) according to the RECIST v.1.1 recorded from randomization until disease progression or death due to any cause, whichever occurred first. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. SD was defined as PR that the sum increases by less than 20% from the nadir, (smallest sum of diameters consider baseline and all assessments prior to the time point under evaluation), but enough that a previously documented 30% decrease no longer holds.

Time frame:
From date of randomization until PD or death, whichever occurred first (maximum up to approximately 26 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With DC in Biomarker-Positive Subgroup
Percentage of participantsAvelumab + AxitinibSunitinib
Percentage of Participants With DC in Biomarker-Positive Subgroup84.4 (79.6 to 88.6)71.0 (65.4 to 76.2)
SecondaryTTR in Biomarker-Positive Subgroup

TTR was defined as the time from randomization to the first documentation of objective tumor response (CR or PR) according to RECIST v1.1 which is subsequently confirmed. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

Time frame:
From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to approximately 26 months)
Reported as:
Median · Months
TTR in Biomarker-Positive Subgroup
MonthsAvelumab + AxitinibSunitinib
TTR in Biomarker-Positive Subgroup1.6 (1.2 to 10.1)3.0 (1.2 to 11.6)
SecondaryDR in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups

DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of PD or death due to any cause, whichever occurred first. As per RECIST version 1.1, CR: disappearance of all target and non-target lesions, and sustained for at least 4 weeks. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \<10 mm. PR: at least 30%\< in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions. PD: defined as at least a 20% \> in sum of diameters of target lesions, taking as reference the smallest sum on study (this included baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute increase of at least 5 mm. Appearance of one or more new lesions was also considered progression.

Time frame:
From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 26 months)
Reported as:
Median · Months
DR in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups
MonthsAvelumab + AxitinibSunitinib
PD-L1 Positive TumorsNA (NA to NA)NA (10.9 to NA)
PD-L1 Negative TumorsNA (11.1 to NA)NA (9.0 to NA)
SecondaryNumber of Participants With Positive Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb) of Avelumab When Used in Combination With Axitinib
Time frame:
From start of treatment until 30 days after the end of avelumab treatment (maximum up to approximately 89 months)
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb) of Avelumab When Used in Combination With Axitinib
ParticipantsAvelumab + Axitinib
ADA Positive77
nAb Positive51
SecondaryTime to Symptom Deterioration (TTD) for Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index - Disease Related Symptoms (FKSI-DRS)

TTD was defined as the time from date of randomization to the first time the participant's score showed a 3-point or greater decrease in FKSI-DRS. FKSI was used to assess symptoms and quality of life (QoL) for those diagnosed with advanced kidney cancer and it consisted of 19 questions. A 9-item subscale of the FKSI known as FKSI-Disease Related Symptoms subscale (FKSI-DRS). This subscale included 9 items: lack of energy, pain, losing weight, bone pain, fatigue, shortness of breath, coughing, bothered by fevers, and hematuria. Each of the 9 items was answered on a 5-point Likert-type scale ranging from 0 to 4 (0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI-DRS score = sum of the 9 item scores; total range: 0 - 36; 0 (no symptoms) to 36 (very much); higher score indicated greater presence of symptoms.

Time frame:
Date of randomization to the first time the participant's score showed a 3-point or greater decrease in FKSI-DRS (maximum up to approximately 26 months)
Reported as:
Median · Months
Time to Symptom Deterioration (TTD) for Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index - Disease Related Symptoms (FKSI-DRS)
MonthsAvelumab + AxitinibSunitinib
Time to Symptom Deterioration (TTD) for Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index - Disease Related Symptoms (FKSI-DRS)4.2 (4.2 to 5.7)6.3 (5.5 to 8.3)
SecondaryChange From Baseline in European Quality of Life (EuroQol) 5-Dimension 5 Levels (EQ-5D-5L) Utility Score

EQ-5D-5L is a 5-item participant-completed questionnaire designed to assess health status in terms of a single utility score. EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Overall scores ranged from 0 to 1, with low scores representing a higher level of dysfunction. Published UK weights were used to create a single summary utility score. Utility scores range from -0.594 to 1, with higher scores representing better health status.

Time frame:
Baseline, Day 1 of Cycle 2 to Cycle 60, End of treatment (any Day from Day 1 of dosing; maximum up to approximately 89 months)
Reported as:
Mean · Units on a scale
Change From Baseline in European Quality of Life (EuroQol) 5-Dimension 5 Levels (EQ-5D-5L) Utility Score
Units on a scaleAvelumab + AxitinibSunitinib
Cycle 2 (Day 1)-0.034 ± 0.17430.001 ± 0.1632
Cycle 3 (Day 1)-0.023 ± 0.1826-0.017 ± 0.1804
Cycle 4 (Day 1)-0.029 ± 0.1829-0.022 ± 0.1667
Cycle 5 (Day 1)-0.019 ± 0.1622-0.016 ± 0.1826
Cycle 6 (Day 1)-0.025 ± 0.1787-0.003 ± 0.1967
Cycle 7 (Day 1)-0.018 ± 0.16510.008 ± 0.1618
Cycle 8 (Day 1)-0.029 ± 0.18480.002 ± 0.1731
Cycle 9 (Day 1)-0.029 ± 0.2021-0.011 ± 0.1662
Cycle 10 (Day 1)-0.025 ± 0.1935-0.018 ± 0.1617
Cycle 11 (Day 1)-0.020 ± 0.18540.004 ± 0.1642
Cycle 12 (Day 1)-0.026 ± 0.1875-0.016 ± 0.1712
Cycle 13 (Day 1)-0.026 ± 0.1777-0.017 ± 0.1549
Cycle 14 (Day 1)-0.036 ± 0.1938-0.006 ± 0.1600
Cycle 15 (Day 1)-0.036 ± 0.18920.018 ± 0.1487
Cycle 16 (Day 1)-0.044 ± 0.17570.020 ± 0.1663
Cycle 17 (Day 1)-0.050 ± 0.1950-0.000 ± 0.1675
Cycle 18 (Day 1)-0.040 ± 0.1667-0.027 ± 0.1765
Cycle 19 (Day 1)-0.059 ± 0.19590.003 ± 0.1665
Cycle 20 (Day 1)-0.050 ± 0.19420.001 ± 0.1538
Cycle 21 (Day 1)-0.048 ± 0.1902-0.004 ± 0.1904
Cycle 22 (Day 1)0.037 ± 0.19190.002 ± 0.1561
Cycle 23 (Day 1)-0.033 ± 0.2021-0.028 ± 0.1729
Cycle 24 (Day 1)-0.036 ± 0.19820.004 ± 0.1618
Cycle 25 (Day 1)-0.019 ± 0.1825-0.007 ± 0.1678
Cycle 26 (Day 1)-0.039 ± 0.1927-0.009 ± 0.1471
Cycle 27 (Day 1)-0.046 ± 0.22330.014 ± 0.1492
Cycle 28 (Day 1)-0.039 ± 0.2060-0.007 ± 0.1639
Cycle 29 (Day 1)-0.019 ± 0.20950.017 ± 0.1601
Cycle 30 (Day 1)-0.032 ± 0.2244-0.003 ± 0.1557
Cycle 31 (Day 1)-0.042 ± 0.2246-0.009 ± 0.1508
Cycle 32 (Day 1)-0.044 ± 0.20950.032 ± 0.1255
Cycle 33 (Day 1)-0.051 ± 0.2294-0.060 ± 0.3550
Cycle 34 (Day 1)-0.029 ± 0.17760.038 ± 0.1558
Cycle 35 (Day 1)-0.010 ± 0.1442-0.002 ± 0.1610
Cycle 36 (Day 1)-0.016 ± 0.15990.030 ± 0.1551
Cycle 37 (Day 1)-0.027 ± 0.15070.052 ± 0.1601
Cycle 38 (Day 1)-0.016 ± 0.14590.057 ± 0.1666
Cycle 39 (Day 1)-0.042 ± 0.15690.052 ± 0.1386
Cycle 40 (Day 1)-0.021 ± 0.14840.060 ± 0.1232
Cycle 41 (Day 1)-0.030 ± 0.14920.056 ± 0.1853
Cycle 42 (Day 1)-0.021 ± 0.16340.034 ± 0.1585
Cycle 43 (Day 1)-0.031 ± 0.13340.011 ± 0.2062
Cycle 44 (Day 1)-0.028 ± 0.13000.016 ± 0.2114
Cycle 45 (Day 1)-0.050 ± 0.14420.007 ± 0.2191
Cycle 46 (Day 1)-0.042 ± 0.1380-0.007 ± 0.2495
Cycle 47 (Day 1)-0.019 ± 0.1240-0.015 ± 0.2335
Cycle 48 (Day 1)-0.025 ± 0.15660.009 ± 0.2833
Cycle 49 (Day 1)-0.028 ± 0.13560.010 ± 0.1873
Cycle 50 (Day 1)-0.028 ± 0.13590.028 ± 0.2507
Cycle 51 (Day 1)-0.011 ± 0.1304-0.010 ± 0.2594
Cycle 52 (Day 1)-0.036 ± 0.1265-0.035 ± 0.2524
Cycle 53 (Day 1)-0.084 ± 0.14370.048 ± 0.1308
Cycle 54 (Day 1)-0.040 ± 0.14250.078 ± 0.1157
Cycle 55 (Day 1)-0.046 ± 0.11210.051 ± 0.1060
Cycle 56 (Day 1)-0.083 ± 0.10810.025 ± 0.1796
Cycle 57 (Day 1)-0.104 ± 0.13470.031 ± NA
Cycle 58 (Day 1)-0.078 ± 0.14080.031 ± NA
Cycle 59 (Day 1)-0.106 ± 0.1053—
Cycle 60 (Day 1)-0.040 ± 0.1167—
End of Treatment-0.111 ± 0.2464-0.069 ± 0.2375
SecondaryChange From Baseline in EQ-5D Visual Analogue Scale (VAS) Score

EQ-VAS records the participant's self-rated health status from 0 (worst imaginable health status) to 100 (best imaginable health status), where higher scores indicated better health status.

Time frame:
Baseline, Day 1 of Cycle 2 to Cycle 60, End of treatment (any Day from Day 1 of dosing; maximum up to approximately 89 months)
Reported as:
Mean · Units on a scale
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) Score
Units on a scaleAvelumab + AxitinibSunitinib
Cycle 2 (Day 1)-0.9 ± 16.12-0.2 ± 15.85
Cycle 3 (Day 1)-0.4 ± 16.390.4 ± 16.44
Cycle 4 (Day 1)-0.1 ± 17.230.7 ± 17.26
Cycle 5 (Day 1)0.4 ± 16.661.8 ± 16.16
Cycle 6 (Day 1)1.3 ± 16.052.6 ± 15.35
Cycle 7 (Day 1)1.2 ± 16.343.3 ± 14.91
Cycle 8 (Day 1)1.4 ± 16.542.9 ± 13.84
Cycle 9 (Day 1)2.0 ± 16.063.3 ± 13.77
Cycle 10 (Day 1)1.6 ± 15.122.4 ± 14.46
Cycle 11 (Day 1)2.5 ± 15.704.1 ± 12.91
Cycle 12 (Day 1)2.1 ± 14.722.6 ± 14.59
Cycle 13 (Day 1)3.0 ± 14.392.7 ± 14.29
Cycle 14 (Day 1)2.7 ± 15.073.0 ± 13.98
Cycle 15 (Day 1)3.1 ± 14.974.7 ± 13.63
Cycle 16 (Day 1)2.9 ± 15.083.6 ± 14.02
Cycle 17 (Day 1)3.0 ± 15.443.2 ± 12.88
Cycle 18 (Day 1)3.2 ± 15.312.0 ± 13.69
Cycle 19 (Day 1)4.5 ± 15.613.0 ± 13.10
Cycle 20 (Day 1)3.9 ± 15.153.1 ± 12.58
Cycle 21 (Day 1)3.7 ± 16.302.1 ± 13.00
Cycle 22 (Day 1)4.3 ± 16.432.6 ± 12.82
Cycle 23 (Day 1)3.7 ± 16.901.3 ± 15.16
Cycle 24 (Day 1)3.3 ± 18.704.5 ± 13.45
Cycle 25 (Day 1)4.6 ± 15.284.2 ± 14.42
Cycle 26 (Day 1)4.4 ± 17.103.4 ± 13.00
Cycle 27 (Day 1)4.7 ± 16.595.4 ± 13.43
Cycle 28 (Day 1)6.3 ± 16.085.0 ± 13.84
Cycle 29 (Day 1)4.8 ± 15.445.4 ± 14.24
Cycle 30 (Day 1)6.0 ± 15.785.3 ± 14.61
Cycle 31 (Day 1)5.7 ± 15.425.2 ± 14.88
Cycle 32 (Day 1)5.4 ± 16.356.0 ± 13.57
Cycle 33 (Day 1)5.5 ± 16.073.6 ± 20.61
Cycle 34 (Day 1)4.8 ± 15.256.1 ± 15.91
Cycle 35 (Day 1)6.0 ± 14.536.4 ± 15.61
Cycle 36 (Day 1)6.0 ± 15.635.2 ± 17.11
Cycle 37 (Day 1)5.8 ± 14.634.5 ± 15.86
Cycle 38 (Day 1)5.3 ± 14.584.3 ± 17.58
Cycle 39 (Day 1)5.3 ± 14.045.9 ± 15.75
Cycle 40 (Day 1)6.0 ± 15.004.7 ± 18.17
Cycle 41 (Day 1)5.6 ± 13.696.2 ± 18.37
Cycle 42 (Day 1)5.3 ± 13.685.4 ± 18.19
Cycle 43 (Day 1)6.6 ± 11.645.4 ± 20.14
Cycle 44 (Day 1)4.9 ± 13.385.1 ± 19.77
Cycle 45 (Day 1)6.3 ± 12.551.5 ± 17.97
Cycle 46 (Day 1)6.7 ± 13.250.3 ± 19.31
Cycle 47 (Day 1)5.4 ± 11.102.5 ± 18.07
Cycle 48 (Day 1)4.4 ± 11.733.5 ± 21.77
Cycle 49 (Day 1)4.2 ± 12.211.9 ± 21.42
Cycle 50 (Day 1)4.8 ± 13.072.9 ± 20.53
Cycle 51 (Day 1)5.8 ± 12.362.1 ± 22.93
Cycle 52 (Day 1)4.2 ± 11.371.5 ± 19.94
Cycle 53 (Day 1)3.2 ± 11.437.7 ± 16.22
Cycle 54 (Day 1)4.6 ± 11.547.5 ± 13.34
Cycle 55 (Day 1)4.6 ± 11.657.8 ± 17.89
Cycle 56 (Day 1)-0.6 ± 8.08-6.0 ± 5.66
Cycle 57 (Day 1)-1.9 ± 10.67-2.0 ± NA
Cycle 58 (Day 1)-2.1 ± 8.59-2.0 ± NA
Cycle 59 (Day 1)0.0 ± 9.35—
Cycle 60 (Day 1)-1.7 ± 16.07—
End of treatment-5.0 ± 19.92-4.3 ± 19.63

Adverse events

Collected over From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Avelumab + Axitinib284/442 (64.3%)231/434 (53.2%)429/434 (98.8%)
Sunitinib296/444 (66.7%)166/439 (37.8%)433/439 (98.6%)
Most frequent serious events
Showing 10 of 326
Most frequent serious events
EventAvelumab + AxitinibSunitinib
DiarrhoeaGastrointestinal disorders12/4343/439
Abdominal painGastrointestinal disorders2/43412/439
Acute myocardial infarctionCardiac disorders11/4340/439
Disease progressionGeneral disorders10/4347/439
AnaemiaBlood and lymphatic system disorders1/43410/439
Acute kidney injuryRenal and urinary disorders9/4349/439
DyspnoeaRespiratory, thoracic and mediastinal disorders8/4346/439
Acute coronary syndromeCardiac disorders6/4340/439
Atrial fibrillationCardiac disorders6/4340/439
Adrenal insufficiencyEndocrine disorders6/4340/439
Most frequent other events
Showing 10 of 100
Most frequent other events
EventAvelumab + AxitinibSunitinib
DiarrhoeaGastrointestinal disorders303/434228/439
HypertensionVascular disorders236/434168/439
FatigueGeneral disorders205/434194/439
NauseaGastrointestinal disorders186/434185/439
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders160/434162/439
ArthralgiaMusculoskeletal and connective tissue disorders157/43483/439
DysphoniaRespiratory, thoracic and mediastinal disorders148/43420/439
CoughRespiratory, thoracic and mediastinal disorders147/434103/439
Decreased appetiteMetabolism and nutrition disorders141/434144/439
HypothyroidismEndocrine disorders135/43489/439

Baseline characteristics

Full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(Years)Avelumab + AxitinibSunitinibTotal
Mean60.86 ± 9.9560.66 ± 10.2860.76 ± 10.11
Sex: Female, Male
Sex: Female, Male(Participants)Avelumab + AxitinibSunitinibTotal
Female126100226
Male316344660
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Avelumab + AxitinibSunitinibTotal
Hispanic or Latino191837
Not Hispanic or Latino388377765
Unknown or Not Reported354984
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Avelumab + AxitinibSunitinibTotal
American Indian or Alaska Native448
Asian7063133
Native Hawaiian or Other Pacific Islander011
Black or African American101020
White332334666
More than one race000
Unknown or Not Reported263258
08

Study locations

270 sites
  • Southern Cancer Center
    Daphne, Alabama 36526, United States
  • Southern Cancer Center
    Mobile, Alabama 36607, United States
  • Southern Cancer Center
    Mobile, Alabama 36608, United States
  • Tower Hematology Oncology Medical Group
    Beverly Hills, California 90211, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • City of Hope
    Duarte, California 91010, United States
  • Keck Hospital of USC
    Los Angeles, California 90033, United States
  • Los Angeles General Medical Center
    Los Angeles, California 90033, United States
  • USC IDS Pharmacy
    Los Angeles, California 90033, United States
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Cedars-Sinai Advanced Health Sciences Pavilion
    Los Angeles, California 90048, United States
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
    Los Angeles, California 90048, United States
  • Cedars-Sinai
    Los Angeles, California 90048, United States
  • Rocky Mountain Cancer Centers
    Aurora, Colorado 80012, United States
  • University of Colorado Cancer Center Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital - Clinical Trials Office (CTO)
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Rocky Mountain Cancer Centers
    Colorado Springs, Colorado 80907, United States
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
  • Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Investigational Drug Service- Emory University
    Atlanta, Georgia 30322, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
  • East Jefferson General Hospital
    Metairie, Louisiana 70006, United States
  • East Jefferson Hematology-Oncology Metairie Physician Service Inc.
    Metairie, Louisiana 70006, United States
  • New England Cancer Specialists
    Kennebunk, Maine 04043, United States
  • New England Cancer Specialists
    Scarborough, Maine 04074, United States
  • New England Cancer Specialists
    Topsham, Maine 04086, United States
  • Oncology Investigational Drug Services- The Sidney Kimmel Cancer Center at Johns Hopkins Hospital
    Baltimore, Maryland 21231, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital (MGH)
    Boston, Massachusetts 02114, United States
  • Massachusetts General Hospital Clinical Trials Pharmacy
    Boston, Massachusetts 02114, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center (BIDMC)
    Boston, Massachusetts 02215, United States
  • Beth Israel Deaconess Medical Center Pharmacy - BIDMC
    Boston, Massachusetts 02215, United States
  • Dana - Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Baystate Franklin Medical Center
    Greenfield, Massachusetts 01301, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Barnes-Jewish Hospital, Siteman Cancer Center - St. Peters
    City of Saint Peters, Missouri 63376, United States
  • Barnes-Jewish Hospital, Siteman Cancer Center - West County
    Creve Coeur, Missouri 63141, United States
  • Barnes-Jewish Hospital, Siteman Cancer Center
    St Louis, Missouri 63110, United States
  • Washington University Infusion Center Pharmacy
    St Louis, Missouri 63110, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Barnes-Jewish Hospital, Siteman Cancer Center - South County
    St Louis, Missouri 63129, United States
  • St. Vincent Healthcare
    Billings, Montana 59101, United States
  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana
    Billings, Montana 59102, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 75063, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89148, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12206, United States
  • New York Oncology Hematology, PC
    Albany, New York 12208, United States
  • New York Oncology Hematology, P.C.
    Clifton Park, New York 12065, United States
  • Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy
    Long Island City, New York 11101, United States
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone
    New York, New York 10016, United States
  • NYU Investigational Pharmacy
    New York, New York 10016, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • MSKCC-Monitoring Suite
    New York, New York 10017, United States
  • Evelyn H. Lauder Breast and Imaging Center
    New York, New York 10065, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Sidney Kimmel Center for Prostate and Urologic Cancers
    New York, New York 10065, United States
  • Stony Brook University-Cancer Center
    Stony Brook, New York 11794, United States
  • Stony Brook University
    Stony Brook, New York 11794, United States
  • Novant Health Oncology Specialists
    Winston-Salem, North Carolina 27103, United States
  • Cleveland Clinic Taussig Cancer Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • James Cancer Hospital and Solove Research Institute
    Columbus, Ohio 43210, United States
  • The Ohio State University - GU Clinic
    Columbus, Ohio 43210, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Cancer Care Associates Medical Oncology
    Allentown, Pennsylvania 18104, United States
  • St.Luke's Hospital-Allentown Campus
    Allentown, Pennsylvania 18104, United States
  • Cancer Care Associate Medical Oncology
    Bethlehem, Pennsylvania 18015, United States
  • St. Lukes University Health Network
    Bethlehem, Pennsylvania 18015, United States
  • St.Luke's Cancer Center Anderson
    Easton, Pennsylvania 18045, United States
  • St.Luke's Hospital-Anderson Campus
    Easton, Pennsylvania 18045, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Investigational Drug Service, University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • St.Luke's Quakertown Hospital
    Quakertown, Pennsylvania 18951, United States
  • Henry-Joyce Cancer Clinic
    Nashville, Tennessee 37232, United States
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Texas Oncology - Gulf Coast
    Houston, Texas 77024, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Investigational Product Center (IPC)
    Irving, Texas 75063, United States
  • Investigational Products Center (IPC)
    Irving, Texas 75063, United States
  • Investigational Products Center (lPC)
    Irving, Texas 75063, United States
  • US Oncology Investigational Products Center (IPC)
    Irving, Texas 75063, United States
  • Joe Arrington Cancer Research and Treatment Center
    Lubbock, Texas 79410, United States
  • Rainier Hematology-Oncology, PC
    Puyallup, Washington 98373, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
  • Macquarie University Hospital Pharmacy
    Macquarie University, New South Wales 2109, Australia
  • Macquarie University
    Macquarie University, New South Wales 2109, Australia
  • Nuclear Medicine Department
    Randwick, New South Wales 2031, Australia
  • Pharmacy Department, Clinical Trials
    Randwick, New South Wales 2031, Australia
  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
  • Spectrum Medical Imaging
    Randwick, New South Wales 2031, Australia
  • Division of Cancer Services
    Woolloongabba, Queensland 4102, Australia

Showing the first 100 of 270 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Tucker M, Chen YW, Voss MH, McGregor BA, Bilen MA, Grimm MO, Nathan P, Kollmannsberger C, Tomita Y, Huang B, Amezquita R, Mariani M, di Pietro A, Rini B. Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial. BMJ Oncol. 2024 Jun 12;3(1):e000181. doi: 10.1136/bmjonc-2023-000181. eCollection 2024. PubMed 39886142 ↗
  • Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, Lee JL, Venugopal B, van den Eertwegh AJM, Negrier S, Gurney H, Albiges L, Berger R, Haanen JBAG, Oyervides Juarez V, Rini BI, Larkin J, Nole F, Schmidinger M, Atkins MB, Tomita Y, Ellers-Lenz B, Hoffman J, Sandner R, Wang J, di Pietro A, Motzer RJ. Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial. Ann Oncol. 2025 Apr;36(4):387-392. doi: 10.1016/j.annonc.2024.12.008. Epub 2024 Dec 18. PubMed 39706335 ↗
  • Grimm MO, Oya M, Choueiri TK, Motzer RJ, Schmidinger M, Quinn DI, Gravis-Mescam G, Verzoni E, Van den Eertwegh AJM, di Pietro A, Mariani M, Wang J, Thomaidou D, Albiges L. Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial. Eur Urol. 2024 Jan;85(1):8-12. doi: 10.1016/j.eururo.2023.09.016. Epub 2023 Oct 16. PubMed 37852850 ↗
  • Rini BI, Atkins MB, Choueiri TK, Teresi RE, Rosbrook B, Thakur M, Hutson TE. Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinoma. Future Oncol. 2023 Dec;19(40):2623-2629. doi: 10.2217/fon-2023-0233. Epub 2023 Aug 1. PubMed 37526095 ↗
  • Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2. PubMed 37146227 ↗
  • Haanen JBAG, Larkin J, Choueiri TK, Albiges L, Rini BI, Atkins MB, Schmidinger M, Penkov K, Michelon E, Wang J, Mariani M, di Pietro A, Motzer RJ. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. ESMO Open. 2023 Jun;8(3):101210. doi: 10.1016/j.esmoop.2023.101210. Epub 2023 Apr 25. PubMed 37104931 ↗
  • Rini BI, Moslehi JJ, Bonaca M, Schmidinger M, Albiges L, Choueiri TK, Motzer RJ, Atkins MB, Haanen J, Mariani M, Wang J, Hariharan S, Larkin J. Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. J Clin Oncol. 2022 Jun 10;40(17):1929-1938. doi: 10.1200/JCO.21.01806. Epub 2022 Mar 3. PubMed 35239416 ↗
  • Masters JC, Khandelwal A, di Pietro A, Dai H, Brar S. Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma. CPT Pharmacometrics Syst Pharmacol. 2022 Apr;11(4):458-468. doi: 10.1002/psp4.12771. Epub 2022 Feb 27. PubMed 35166465 ↗
  • Rini BI, Atkins MB, Choueiri TK, Thomaidou D, Rosbrook B, Thakur M, Hutson TE. Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2021 Oct;19(5):e306-e312. doi: 10.1016/j.clgc.2021.03.019. Epub 2021 Apr 5. PubMed 33947608 ↗
  • Choueiri TK, Larkin J, Pal S, Motzer RJ, Rini BI, Venugopal B, Alekseev B, Miyake H, Gravis G, Bilen MA, Hariharan S, Chudnovsky A, Ching KA, Mu XJ, Mariani M, Robbins PB, Huang B, di Pietro A, Albiges L. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open. 2021 Jun;6(3):100101. doi: 10.1016/j.esmoop.2021.100101. Epub 2021 Apr 23. PubMed 33901870 ↗
  • Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, Mu XJ, Ching KA, Uemura M, Pal SK, Alekseev B, Gravis G, Campbell MT, Penkov K, Lee JL, Hariharan S, Wang X, Zhang W, Wang J, Chudnovsky A, di Pietro A, Donahue AC, Choueiri TK. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat Med. 2020 Nov;26(11):1733-1741. doi: 10.1038/s41591-020-1044-8. Epub 2020 Sep 7. PubMed 32895571 ↗
  • Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, Kollmannsberger C, Gravis-Mescam G, Uemura M, Lee JL, Grimm MO, Gurney H, Schmidinger M, Larkin J, Atkins MB, Pal SK, Wang J, Mariani M, Krishnaswami S, Cislo P, Chudnovsky A, Fowst C, Huang B, di Pietro A, Albiges L. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020 Aug;31(8):1030-1039. doi: 10.1016/j.annonc.2020.04.010. Epub 2020 Apr 25. PubMed 32339648 ↗
  • Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16. PubMed 30779531 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Aug 2023, 89 months.

Results were first posted in Oct 2024, 1 year 1 month after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 59. This study's 89 months is above that.

Counting every sponsor, half of 61 studies reached it within 56 months; a quarter within 42 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2016
First posted
Feb 17, 2016
StartActual
Mar 23, 2016
Primary completionActual
Aug 31, 2023
CompletionActual
Jun 26, 2024
Results first posted
Oct 29, 2024
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02684006
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 17, 2016
Start date
Mar 23, 2016
Primary completion
Aug 31, 2023
Completion
Jun 26, 2024
Results posted
Oct 29, 2024
Last update
Jul 30, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Avelumab · Axitinib

Start the discussion